Replimune Group (REPL) Stock Price, News & Analysis

Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $8.68 to $9.19
• 50-Day Range: $6.92 to $14.31
• 52-Week Range: $4.92 to $17.00
• Volume: 362,638 shs
• Average Volume: 864,212 shs
• Market Capitalization: $696.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.43
• Consensus Rating: Buy

Replimune Group Stock Analysis - MarketRank™

Replimune Group scored higher than 83% of companies evaluated by MarketBeat, and ranked 264th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Replimune Group has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Replimune Group has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Replimune Group are expected to grow in the coming year, from ($2.97) to ($2.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Replimune Group is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Replimune Group is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Replimune Group has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.57% of the float of Replimune Group has been sold short.

Short Interest Ratio / Days to Cover

Replimune Group has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Replimune Group has recently decreased by 7.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Replimune Group does not currently pay a dividend.

Dividend Growth

Replimune Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.28

Percentage of Shares Shorted

12.57% of the float of Replimune Group has been sold short.

Short Interest Ratio / Days to Cover

Replimune Group has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Replimune Group has recently decreased by 7.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.51

News Sentiment

Replimune Group has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Replimune Group this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for REPL on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Replimune Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.80% of the stock of Replimune Group is held by insiders.

Percentage Held by Institutions

92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

REPL Stock Analysis - Frequently Asked Questions

How have REPL shares performed this year?

Replimune Group's stock was trading at $12.11 at the beginning of the year. Since then, REPL stock has decreased by 25.3% and is now trading at $9.05.
View the best growth stocks for 2025 here.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.09.

When did Replimune Group IPO?

Replimune Group (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's top institutional investors include Exchange Traded Concepts LLC (0.01%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Pamela Esposito, Sushil Patel, Tanya Lewis, Konstantinos Xynos, Emily Luisa Hill, Christopher Sarchi and Andrew Schwendenman.
View institutional ownership trends.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 4/28/2025
• Next Earnings (Estimated): 5/15/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REPL
• CIK: 1737953
• Web: www.replimune.com
• Phone: (781) 222-9600
• Fax: N/A
• Employees: 210
• Year Founded: 2015

Price Target and Rating

• Average Stock Price Target: $19.43
• High Stock Price Target: $27.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +114.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-215,790,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.84%
• Return on Assets: -42.97%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 11.43
• Quick Ratio: 11.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.26 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 77,015,000
• Free Float: 70,238,000
• Market Cap: $696.99 million
• Optionable: Optionable
• Beta: 1.26